Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Intellia Therapeutics Inc NTLA

Healthcare Biotechnology

Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its... see more

Add To Watchlist

Recent & Breaking News (NDAQ:NTLA)

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2020 Earnings and Company Updates

GlobeNewswire July 30, 2020

Intellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire June 5, 2020

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire June 2, 2020

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire June 1, 2020

Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments

PR Newswire June 1, 2020

Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy

GlobeNewswire May 12, 2020

Intellia Therapeutics Announces First Quarter 2020 Financial Results

GlobeNewswire May 7, 2020

Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer

GlobeNewswire April 30, 2020

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2020 Earnings and Company Updates

GlobeNewswire April 30, 2020

Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy

GlobeNewswire April 28, 2020

FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics

GlobeNewswire March 31, 2020

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results

GlobeNewswire February 27, 2020

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2019 Earnings and Company Update

GlobeNewswire February 20, 2020

Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia's Engineering the Genome Conference

GlobeNewswire February 10, 2020

Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones

GlobeNewswire January 9, 2020

Intellia Therapeutics to Present at Evercore ISI 2nd Annual HealthCONx Conference

GlobeNewswire November 26, 2019

Intellia Therapeutics Announces Third Quarter 2019 Financial Results

GlobeNewswire October 31, 2019

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2019 Earnings and Company Update

GlobeNewswire October 24, 2019

Intellia Therapeutics Presents In Vivo and Ex Vivo Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)

GlobeNewswire October 24, 2019

Intellia Therapeutics Announces Presentations at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)

GlobeNewswire October 16, 2019